Market research
1T3.F Syndax Pharmaceuticals, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 27.67
- Dividend yield
- Not available
- Beta
- 0.37
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US87164F1057
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 27.67
- Dividend yield
- Not available
- Beta
- 0.37
About
About Syndax Pharmaceuticals, Inc
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 1T3.F discussion.
5 years, 5 months ago
Syndax Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 19.2% below its 200 day moving average.
From a valuation standpoint, the stock is 54.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 600.3.
Syndax Pharmaceuticals, Inc's total revenue rose by 0.3% to $380K since the same quarter in the previous year.
Its net income has dropped by 45.9% to $-20M since the same quarter in the previous year.
Finally, its free cash flow fell by 22.8% to $-16M since the same quarter in the previous year.
Based on the above factors, Syndax Pharmaceuticals, Inc gets an overall score of 2/5.